ATS View
한국어

GC Biopharma KRX:006280KOSPI

녹십자 · Korean news coverage and regulatory filings, organized.

한국어
Articles, 24h14
Articles, 7 days54
DART filings, 7 days0
Articles tracked54since Sep 11

In Q2 2026, GC Biopharma reported revenue of ₩421bn, down 15.8% year on year, and operating profit of ₩1.7bn. GC Biopharma (녹십자) appeared in 54 Korean news articles and 0 DART filings over the past seven days. Coverage peaked on Sep 14 with 29 articles. The most common catalyst was clinical & approvals (10). It was most often mentioned alongside Bukwang Pharmaceutical Ind, Chong Kun Dang Pharmaceutical and GC Cell.

GC Biopharma quarterly results consolidated, KRW

QuarterRevenueYoYOperating profitNet income
Q2 2026₩421bn-15.8%₩1.7bn₩1.1bn
Q1 2026₩436bn+13.5%₩11.7bn₩20.1bn
Q4 2025 derived₩498bn+12.9%₩4.6bn−₩103bn
Q3 2025₩609bn+31.1%₩29.2bn₩18.1bn
Q2 2025₩500bn+19.9%₩27.4bn₩32.7bn
Q1 2025₩384bn+7.6%₩8.0bn₩22.3bn
Q4 2024 derived₩441bn+8.9%−₩10.1bn−₩38.7bn
Q3 2024₩465bn+5.8%₩39.6bn₩35.8bn

Key accounts from quarterly, half-year and annual reports filed on DART. Q4 is derived as full-year minus nine-month figures. Figures may differ from preliminary earnings releases.

GC Biopharma top stories 2 weeks, by number of outlets

  1. 1
    GC녹십자의료재단, 케냐 보건부 공무원 초청연수 진행
    11 outlets · 11 articlesFirst report Sep 14 09:07 FETV
  2. 2
    GC녹십자 "코로나19 mRNA 백신 임상 2상 IND 승인"
    5 outlets · 6 articlesFirst report Sep 11 08:37 SBS BizClinical trial
  3. 3
    GC녹십자의료재단, ‘이종욱 펠로우십’ 감염병 전문가과정 마무리
    5 outlets · 5 articlesFirst report Sep 11 13:24 PRESS9
  4. 4
    GC녹십자의료재단 "KOICA 케냐 보건부 초청 연수 개시"
    5 outlets · 5 articlesFirst report Sep 14 09:14 아시아경제
  5. 5
    GC녹십자, 코로나19 mRNA 백신 임상 2상 계획 승인
    2 outlets · 2 articlesFirst report Sep 12 22:42 메디포뉴스Clinical trial
  6. 6
    GC녹십자의료재단, '이종욱 펠로우십' 감염병 전문가 연수 성료
    2 outlets · 2 articlesFirst report Sep 11 13:40 메디파나뉴스

Latest GC Biopharma news Korean headlines